Irritable bowel symptoms, use of healthcare, costs, sickness and disability pension benefits: A long-term population-based study

Poulsen, Chalotte Heinsvig; Eplov, Lene Falgaard; Hjorthøj, Carsten; Hastrup, Lene Halling; Eliasen, Marie; Dantoft, Thomas Meinertz; Schröder, Andreas; Jørgensen, Torben

doi:10.1177/1403494818776168

Cited by 22 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…82 Additional costs to society might be incurred if patients who are unable to work due to their IBS symptoms claim sickness or disability benefits. In a longitudinal population-based study in Denmark, the expected number of weeks on sickness benefits was 61% higher among those with IBS symptoms, which remained statistically significant following adjustment for age, sex, time in education, comorbidity and mental vulnerability (P=0.01) 83 . There was also a trend towards an increased number of weeks on disability benefits among those with IBS symptoms, compared with people without IBS symptoms, but this difference was not statistically significant following adjusted analysis 83 .…”

Section: [H2] Issues For Societymentioning

confidence: 94%

Global burden of irritable bowel syndrome: trends, predictions and risk factors

Black

Ford

2020

Nat Rev Gastroenterol Hepatol

322

237

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction worldwide and is defined according to patterns of gastrointestinal symptoms, as described by the Rome diagnostic criteria. However, these criteria, developed with reference to research conducted largely in Western populations, might be limited in their applicability to other countries and cultures. Epidemiological data show a wide variation in the prevalence of IBS globally and more rigorous studies are needed to accurately determine any differences that might exist between countries and potential explanations. The effect of IBS on the individual, in terms of their quality of life, and on healthcare delivery and society, in terms of economic costs, is considerable. Although the magnitude of these effects seems to be comparable between nations, their precise nature can vary based on the existence of societal and cultural differences. The pathophysiology of IBS is complex and incompletely understood; genetics, diet and the gut microbiome are all recognised risk factors, but the part they play might be influenced by geography and culture, and hence their relative importance might vary between countries. This Review aims to provide an overview of the burden of IBS in a global context, to discuss future implications for the care of people with IBS worldwide, and to identify key areas for further research.

show abstract

Section: [H2] Issues For Societymentioning

confidence: 94%

Global burden of irritable bowel syndrome: trends, predictions and risk factors

Black

Ford

2020

Nat Rev Gastroenterol Hepatol

322

237

View full text Add to dashboard Cite

show abstract

“…However a Finish group has repeatedly described absence of associations between health care utilization and mental distress in IBS (101,102). In a Danish study mental vulnerability in IBS patients explained some, but not all, of the use of healthcare and social benefits (103). Further an extensive systematic review regarding health care utilization of patients with IBS and non-ulcer dyspepsia, suggested that symptom severity explains a small proportion of health care seeking behavior.…”

Section: Health Care Utilizationmentioning

confidence: 99%

Exploring the Biopsychosocial Model in Irritable Bowel Syndrome : with emphasis on stress, comorbidities and fatigue

Norlin

2020

Linköping University Medical Dissertations

View full text Add to dashboard Cite

Background Irritable bowel syndrome (IBS) is a common, chronic, relapsing, and sometimes disabling, symptom-based disorder of gut brain interactions. It has got a female predominance and occurs in all ages, with a slight decrease among elderly. The IBS symptoms can affect everyday work and social life in addition to an increased use of health care resources. Most IBS patients are diagnosed and helped in primary health care (PHC). For many patients, available treatment is insufficient. It is known that both extraintestinal symptoms such as fatigue, as well as comorbidities such as mood disorders, chronic pain syndromes, and insomnia contribute to the illness burden, often to a larger extent than the gastrointestinal symptoms as such. Eventhough the pathophysiology of IBS is not completely known, it is now conceptualized as a disorder of altered brain-gut interactions, where a biopsychosocial model helps in understanding the symptoms. Exposure to stress is thought to play an important role overall in the pathology of IBS, as well as immune activation at least in a subgroup of patients. This thesis aimed to gain deeper understanding of the biopsychosocial mechanisms of IBS and its associations with stress, comorbidities, and fatigue.

show abstract

“…IBS has a negative impact on the quality of life (QOL) and the psychological state of the patient [4]. The disease increases the economic burden on employers as it lowers labor and social capacities of the affected individuals [5,6,7,8]. In general, IBS is a chronic functional gastrointestinal (GI) disorder characterized by recurrent abdominal pain and abnormal bowel habits without structural and biochemical abnormalities [9,10,11].…”

Section: Introductionmentioning

confidence: 99%

Effect of Samryungbaekchul-san Combined with Otilonium Bromide on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Randomized Controlled Trial

Lee

Kim

Baeg

et al. 2019

JCM

View full text Add to dashboard Cite

Conventional and herbal drugs are frequently used together to treat many disorders. Samryungbaekchul-san (SRS, a herbal formula) and otilonium bromide (OB, an antispasmodic agent) are widely used to treat diarrhea-predominant irritable bowel syndrome (D-IBS) in Eastern Asian countries. However, there have been no studies on the co-administration of SRS and OB. Therefore, we aimed to preliminarily assess the feasibility of SRS combined with OB for D-IBS treatment in a pilot double-blind, four-arm, parallel-group, randomized controlled trial (RCT), including 80 patients diagnosed with D-IBS according to the Rome III criteria. The patients were randomly assigned to four treatment groups and were administered drugs for eight weeks after a two-week preparatory period. Follow-up was conducted four weeks after the administration period. The primary outcome was evaluated by using a global D-IBS symptom improvement score; no statistically significant difference was observed between the groups. However, multiple logistic regression analysis of primary outcome scores shows that SRS significantly improved D-IBS symptoms (p < 0.05). For secondary outcomes, better results were observed in the SRS + OB group, in terms of symptoms, including abdominal pain, discomfort, frequency of abdominal pain, and stool form than in OB alone or placebo groups (p < 0.05). In conclusion, the co-administration of SRS and OB might be an effective and safe strategy for the treatment of D-IBS. Large-scale RCTs are warranted to further confirm and clarify these findings.

show abstract

Irritable bowel symptoms, use of healthcare, costs, sickness and disability pension benefits: A long-term population-based study

Abstract: IBS symptoms influence the long-term use and costs of healthcare, as well as the use of social benefits in the general population. Mental vulnerability explained some, but not all, of the use of healthcare and social benefits.

Cited by 22 publications

References 27 publications

Global burden of irritable bowel syndrome: trends, predictions and risk factors

Global burden of irritable bowel syndrome: trends, predictions and risk factors

Exploring the Biopsychosocial Model in Irritable Bowel Syndrome : with emphasis on stress, comorbidities and fatigue

Effect of Samryungbaekchul-san Combined with Otilonium Bromide on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Randomized Controlled Trial

Contact Info

Product

Resources

About